Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model.

Mishra J, Dey A, Singh N, Somvanshi R, Singh S.

Indian J Med Res. 2013 Apr;137(4):767-76.

PMID:
23703346
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.

Khan MA, Owais M.

J Antimicrob Chemother. 2006 Jul;58(1):125-32. Epub 2006 May 18.

PMID:
16709592
[PubMed - indexed for MEDLINE]
Free Article
3.

Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Coukell AJ, Brogden RN.

Drugs. 1998 Apr;55(4):585-612. Review.

PMID:
9561346
[PubMed - indexed for MEDLINE]
4.

Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

Davidson RN, Croft SL, Scott A, Maini M, Moody AH, Bryceson AD.

Lancet. 1991 May 4;337(8749):1061-2.

PMID:
1673494
[PubMed - indexed for MEDLINE]
5.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
[PubMed - indexed for MEDLINE]
6.

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.

Gangneux JP, Sulahian A, Garin YJ, Derouin F.

Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):574-7.

PMID:
8944278
[PubMed - indexed for MEDLINE]
7.

Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

Paul M, Durand R, Fessi H, Rivollet D, Houin R, Astier A, Deniau M.

Antimicrob Agents Chemother. 1997 Aug;41(8):1731-4.

PMID:
9257750
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Liposomal amphotericin B in the treatment of visceral leishmaniasis.

Croft SL, Davidson RN, Thornton EA.

J Antimicrob Chemother. 1991 Oct;28 Suppl B:111-8.

PMID:
1778888
[PubMed - indexed for MEDLINE]
9.

Antileishmanial activity of nano-amphotericin B deoxycholate.

Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S.

J Antimicrob Chemother. 2008 Aug;62(2):376-80. doi: 10.1093/jac/dkn189. Epub 2008 May 2.

PMID:
18453526
[PubMed - indexed for MEDLINE]
Free Article
10.

Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.

Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON, Sundar S.

Adv Exp Med Biol. 2014;808:77-91. doi: 10.1007/978-81-322-1774-9_7.

PMID:
24595612
[PubMed - indexed for MEDLINE]
11.

Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F.

Antimicrob Agents Chemother. 1996 May;40(5):1214-8.

PMID:
8723469
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Yardley V, Croft SL.

Antimicrob Agents Chemother. 1997 Apr;41(4):752-6.

PMID:
9087483
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Brogden RN, Goa KL, Coukell AJ.

Drugs. 1998 Sep;56(3):365-83. Review.

PMID:
9777313
[PubMed - indexed for MEDLINE]
14.

Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.

Roychoudhury J, Sinha R, Ali N.

PLoS One. 2011 Mar 10;6(3):e17376. doi: 10.1371/journal.pone.0017376.

PMID:
21423750
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS.

Mastroianni A.

Infez Med. 2004 Sep;12(3):197-204. Review.

PMID:
15711134
[PubMed - indexed for MEDLINE]
Free Article
16.

[Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].

Rosenthal E, Delaunay P, Jeandel PY, Haas H, Pomares-Estran C, Marty P.

Med Mal Infect. 2009 Oct;39(10):741-4. doi: 10.1016/j.medmal.2009.05.001. Epub 2009 Sep 23. Review. French.

PMID:
19783391
[PubMed - indexed for MEDLINE]
18.

A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.

Yardley V, Croft SL.

Int J Antimicrob Agents. 2000 Feb;13(4):243-8.

PMID:
10755238
[PubMed - indexed for MEDLINE]
19.

Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.

Al-Abdely HM, Graybill JR, Bocanegra R, Najvar L, Montalbo E, Regen SL, Melby PC.

Antimicrob Agents Chemother. 1998 Oct;42(10):2542-8.

PMID:
9756753
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.

Wasan EK, Gershkovich P, Zhao J, Zhu X, Werbovetz K, Tidwell RR, Clement JG, Thornton SJ, Wasan KM.

PLoS Negl Trop Dis. 2010 Dec 7;4(12):e913. doi: 10.1371/journal.pntd.0000913.

PMID:
21151883
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk